At the beginning of January 2024, we signed the final acceptance protocol of the Research and Development Center (CBR) with the general contractor.
‘Now we are starting operational activities aimed at developing and introducing internationally innovative medicinal products to the market. This is all possible because CBR has been equipped with the most modern technological line in Europe,’ emphasizes Mieczysław Starkowicz, president of the management board of Synthaverse.
Thanks to the opening of the new Research and Development Center, the company gains unlimited opportunities to conduct research and development in technologies in which it is an expert, i.e. aseptic processes, freeze-drying and bacterial cultures.
CBR is equipped with a modern technological line that allows comprehensive implementation of such processes as: depyrogenation, filling, loading, freeze-drying, unloading, and capping of finished products. The production capacity of the new line is 20 million vials, in three different formats, per year.
In the CBR building with an area of 2.5 thousand. sq m there are: office and social, production and technical spaces. The facility is equipped with installations adapted to Synthaverse technologies. Among others, a very complex mechanical ventilation and air conditioning system, water generators, nitrogen installations, technical and technological steam installations were installed.
‘It is worth mentioning that the plant, with its advanced solutions, required an equally complex acceptance process. All test results were positive and in accordance with our specifications. Therefore, special thanks are due to the entire Synthaverse team and the project contractor, Karmar,’ adds Mieczysław Starkowicz.
January 2024
